Alnylam Pharma (ALNY) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-193.1M
Depreciation and amortization	8.61M
Deferred income taxes
Non-cash income tax benefit
Non-cash stock-based compensation	39.3M
Charge for 401(k) company stock match
Equity in loss of joint venture (Regulus Therapeutics Inc.)
Collaboration receivables	-1.22M
Income taxes receivable
Prepaid expenses and other assets	-5.59M
Accounts payable	-3.59M
Income taxes payable
Accrued expenses and other	1.72M
Deferred revenue	5.38M
Net cash used in operating activities
Purchases of property and equipment	-24.38M
Purchases of marketable securities
Sales and maturities of marketable securities	605.98M
Net cash provided by (used in) investing activities
Proceeds from issuance of common stock	6.27M
Proceeds from issuance of shares to Novartis	0
Net cash provided by financing activities
Effect of exchange rate on cash
Net decrease in cash and cash equivalents	90.18M
Cash and cash equivalents, beginning of period	180.9M
Cash and cash equivalents, end of period	271.08M

Entities mentioned with ALNY

View All Entities